Compare Ascendis Pharma A/S (ASND) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Paychex, Inc. — how do they compare? Ascendis Pharma A/S trades at $260.65 (market cap $16.67B), while Paychex, Inc. trades at $121.38 (market cap $43.14B). The key difference: Paychex, Inc. is far larger — about 2.6× Ascendis Pharma A/S's market cap, and Paychex, Inc. pays a 3.92% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PAYX | |
|---|---|---|
Market Cap | $16.67B | $43.14B |
Sector | Health | Industrials |
52-Week High | $277.18 | $140.81 |
52-Week Low | $189.74 | $85.57 |
Enterprise Value | $17.04B | $46.63B |
Dividend Yield | — | 3.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
Paychex (PAYX) trades at $120.34, down 0.69% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a 27.03% net income margin and consistent earnings beats, though valuation ratios like a P/E of 24.81 are elevated. Recent news highlights steady small business employment data and product expansion, supporting its core HR services business.
The outlook is mixed: solid fundamentals and dividend payments offer stability, but high valuation and analyst caution (63.33% hold rating) suggest limited near-term upside. Risks include economic sensitivity and debt levels, yet long-term growth in HR outsourcing remains a tailwind for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
